NEW YORK (GenomeWeb News) – 23andMe today announced the expansion of its online study conducted with Genentech for the biotech firm's oncology drug Avastin (bevacizumab).

In a post on 23andMe's blog, the Mountain View, Calif.-based company said that its study with Genentech, called InVite, is now open to any patient in the US who used Avastin before 2013 for treatment of metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer, relapsed glioblastoma, metastatic renal cell carcinoma, or metastatic breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.